JP2005526085A5 - - Google Patents

Download PDF

Info

Publication number
JP2005526085A5
JP2005526085A5 JP2003575997A JP2003575997A JP2005526085A5 JP 2005526085 A5 JP2005526085 A5 JP 2005526085A5 JP 2003575997 A JP2003575997 A JP 2003575997A JP 2003575997 A JP2003575997 A JP 2003575997A JP 2005526085 A5 JP2005526085 A5 JP 2005526085A5
Authority
JP
Japan
Prior art keywords
vaccine
quinolin
imidazo
antigen
amine derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003575997A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005526085A (ja
Filing date
Publication date
Priority claimed from GBGB0206461.6A external-priority patent/GB0206461D0/en
Application filed filed Critical
Publication of JP2005526085A publication Critical patent/JP2005526085A/ja
Publication of JP2005526085A5 publication Critical patent/JP2005526085A5/ja
Pending legal-status Critical Current

Links

JP2003575997A 2002-03-19 2003-03-18 ワクチン接種の改良 Pending JP2005526085A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0206461.6A GB0206461D0 (en) 2002-03-19 2002-03-19 Improvements in vaccination
PCT/EP2003/002878 WO2003077944A1 (en) 2002-03-19 2003-03-18 Improvements in vaccination

Publications (2)

Publication Number Publication Date
JP2005526085A JP2005526085A (ja) 2005-09-02
JP2005526085A5 true JP2005526085A5 (enExample) 2006-03-30

Family

ID=9933281

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003575997A Pending JP2005526085A (ja) 2002-03-19 2003-03-18 ワクチン接種の改良

Country Status (7)

Country Link
US (2) US20050143284A1 (enExample)
EP (1) EP1485125A1 (enExample)
JP (1) JP2005526085A (enExample)
AU (1) AU2003212369A1 (enExample)
CA (1) CA2479315A1 (enExample)
GB (1) GB0206461D0 (enExample)
WO (1) WO2003077944A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003216851B2 (en) * 2002-03-19 2008-04-17 Powderject Research Limited Imidazoquinoline adjuvants for vaccines
NZ540826A (en) 2002-12-20 2008-07-31 3M Innovative Properties Co Aryl / hetaryl substituted imidazoquinolines
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
AU2004264336B2 (en) * 2003-08-05 2010-12-23 3M Innovative Properties Company Formulations containing an immune response modifier
CA2551075A1 (en) * 2003-08-25 2005-03-03 3M Innovative Properties Company Immunostimulatory combinations and treatments
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
ES2544477T3 (es) 2003-10-03 2015-08-31 3M Innovative Properties Company Imidazoquinolinas sustituidas con alcoxi
EP1675596A4 (en) * 2003-10-10 2009-01-21 Powderject Vaccines Inc METHOD
RU2409576C2 (ru) 2003-11-25 2011-01-20 3М Инновейтив Пропертиз Компани Системы, содержащие имидазольное кольцо с заместителями, и способы их получения
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
CN101304748A (zh) 2005-08-22 2008-11-12 加利福尼亚大学董事会 Tlr激动剂
EA200800782A1 (ru) 2005-09-09 2008-08-29 Коли Фармасьютикал Груп, Инк. ПРОИЗВОДНЫЕ АМИДА И КАРБАМАТА N-{2-[4-АМИНО-2-(ЭТОКСИМЕТИЛ)-1Н-ИМИДАЗОЛО[4,5-c]ХИНОЛИН-1-IL]-1,1-ДИМЕТИЛЭТИЛ}МЕТАНСУЛЬФОНАМИДА И СПОСОБЫ
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
WO2007056112A2 (en) 2005-11-04 2007-05-18 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
US8088788B2 (en) 2006-03-15 2012-01-03 3M Innovative Properties Company Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods
US8329721B2 (en) 2006-03-15 2012-12-11 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
EP2700638A1 (en) 2006-05-31 2014-02-26 The Regents Of the University of California Purine analogs
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
HUE025555T2 (en) 2007-02-07 2016-02-29 Univ California Conjugates and applications of synthetic tlr agonists
EP3067048B1 (en) 2007-12-07 2018-02-14 GlaxoSmithKline Biologicals SA Compositions for inducing immune responses
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105325A (en) * 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
GB0023008D0 (en) * 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination

Similar Documents

Publication Publication Date Title
JP2005526085A5 (enExample)
DK1509521T3 (da) 1H-Imidazol[4,5-c]quinolinderivater til behandling af proteinkinaseafhænige sygdomme
AR035586A1 (es) Composicion de vacuna, equipo, metodos para incrementar la respuesta inmune, uso de un derivado de 1h-imidazo(4,5-c)quinolin-4-amina en la fabricacion de un medicamento, y combinacion de componentes para la administracion separada, secuencial o concomitante para el uso en la vacunacion de adn
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
WO2015024667A8 (en) Method for increasing expression of rna-encoded proteins
JP2007534728A5 (enExample)
IL222495A (en) Use of an isolated human antibody tnfa antibody to create a drug for the treatment of idiopathic inflammatory bowel disease, a pharmaceutical product, kit and pre-loaded syringe containing it
CN105491982A (zh) 用于增强透皮递送的肽
WO2003090686A3 (en) Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
HRP20140102T1 (hr) Cjepivo za prevenciju relapsa raka dojke
CA2514224A1 (en) Liquid pharmaceutical formulations of palonosetron
AR035867A1 (es) Una particula semejante a un virus hcv formada por una proteina de envoltura de hcv, un metodo para formar dicha particula, un medicamento que la contiene, una vacuna, un metodo de deteccion, un kit de diagnostico, el uso de cepas de hansenula o saccharomyces para la expresion de una proteina hcv, e
ITMI20031617A1 (it) Microcapsule a doppio strato di polisaccaridi utilizzabili
WO2005010022A3 (en) Agonist polypeptide of receptor for zot and zonulin
WO2005084306A3 (en) Immunogenic compositions for chlamydia pneunomiae
EP1491210A4 (en) THERAPEUTIC MEDICAMENT USING ANTIBODY PRESENTING HOLES PROTEIN NANOTEHICLES AND HIGH PROTEIN NANOTEHICLES
DK1173476T3 (da) Funktionelle sojabönneproteiner
EA200400591A1 (ru) СПОСОБ ВВЕДЕНИЯ ПЕПТИДА ТИМОЗИН α1
HUP0400340A2 (hu) Polipeptidek immunogenitásának csökkentésére szolgáló eljárások
NO20053788L (no) Anvendelse av lupin-konglutin for behandlingen av type II diabetes.
ATE301452T1 (de) Verfahren zur herstellung einer flüssigen dosierungseinheit und kit
EP1583545A4 (en) PHARMACEUTICAL COMPOSITION FOR IMPROVED ADMINISTRATION OF PEPTIDES OF HIV GP41 AND ITS THERAPEUTIC USE
ZA200500556B (en) The pharmaceutical formulation of traditional chinese medicine for abstinence of drug and preparation method and use thereof
WO2004106275A3 (en) Compounds useful in the therapy of alzheimer’s disease and formulations containing them
JP2005506959A5 (enExample)